Edesa Biotech, Inc.
New Form D on file · 2026-06-26 · the record
Edesa Biotech, Inc. filed a Form D with the Securities and Exchange Commission on 2026-06-26.
Edesa Biotech, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 26, 2026. Edesa Biotech, Inc. trades on Nasdaq as EDSA; it was formerly Stellar Biotechnologies, Inc. The filing reports $3.50M sold. Its industry group is Biotechnology. It names Sean MacDonald (Director), Pardeep Nijhawan (Executive Officer, Director), Carlo Sistilli (Director) (SEC Form D, June 26, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Edesa Biotech, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-06-26 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Edesa Biotech, Inc.
Free to see. No signup.
More on the people and the money behind Edesa Biotech, Inc., from the filings we hold.
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Edesa Biotech, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Edesa Biotech, Inc. raises, hires or launches. No email unless you switch it on.
Watch Edesa Biotech, Inc. →Get the full cited report on Edesa Biotech, Inc.
What the filing shows about Edesa Biotech, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Edesa Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Edesa Biotech, Inc.'s address as 100 Spy Court, Markham, A6 L3R 5H6.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Edesa Biotech, Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Edesa Biotech, Inc. is a registered filer with the SEC (CIK 1540159) and has filed since 2025-02-14. 2 filings are on record, the latest on 2026-06-26.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Edesa Biotech, Inc.'s Form D of 2026-06-26 names Sean MacDonald, Pardeep Nijhawan, Carlo Sistilli and 6 more as its officers, directors or promoters.
Its new offerings report $18.50M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week. The dot is this raise, $3.50M, on the same scale — one filing against the whole group's total, so it sits low by construction.
The proceeds from the offering will be used for working capital and general corporate purposes.
Checked away from the filing. What is below does not come from the record on sec.gov.
The title and description the site itself served, answering 200, after redirecting from https://edesabiotech.com. Not a cached copy and not the company's directory entry — what was live when we asked.
Sean MacDonald is named as Director on the Form D that Edesa Biotech, Inc. filed with the SEC on 26 June 2026, one of 9 people that filing names.
Pardeep Nijhawan is named as Executive Officer and Director on the Form D that Edesa Biotech, Inc. filed with the SEC on 26 June 2026, one of 9 people that filing names.
Carlo Sistilli is named as Director on the Form D that Edesa Biotech, Inc. filed with the SEC on 26 June 2026, one of 9 people that filing names.
Michael Brooks is named as Executive Officer on the Form D that Edesa Biotech, Inc. filed with the SEC on 26 June 2026, one of 9 people that filing names.
Peter Weiler is named as Executive Officer on the Form D that Edesa Biotech, Inc. filed with the SEC on 26 June 2026, one of 9 people that filing names.
Joan Chypyha is named as Director on the Form D that Edesa Biotech, Inc. filed with the SEC on 26 June 2026, one of 9 people that filing names.
Charles Olson is named as Director on the Form D that Edesa Biotech, Inc. filed with the SEC on 26 June 2026, one of 9 people that filing names.
Patrick Marshall is named as Director on the Form D that Edesa Biotech, Inc. filed with the SEC on 26 June 2026, one of 9 people that filing names.
David Liu is named as Director on the Form D that Edesa Biotech, Inc. filed with the SEC on 26 June 2026, one of 9 people that filing names.
9 people named on the filing — 3 holding an executive role and 6 as directors only.
Named as of the 2026-06-26 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Edesa Biotech, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Edesa Biotech, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Edesa Biotech, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Edesa Biotech, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Edesa Biotech, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (edesabiotech.com).
Each opens in a new tab, filled in for Edesa Biotech, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.

https://mentionfox.com/funding/edesa-biotech-inc-form-d-26000001